Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
27
LEXX Quote, Financials, Valuation and Earnings
Last price:
$0.57
Seasonality move
:
0.34%
Day range:
$0.55 - $0.70
52-week range:
$0.48 - $2.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.82x
P/B ratio:
5.16x
Volume:
17.8M
Avg. volume:
331.2K
1-year change:
-69.78%
Market cap:
$15.4M
Revenue:
$705.9K
EPS (TTM):
-$0.66
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Lexaria Bioscience Corp. has 760.22% upside to fair value with a price target of $6.00 per share.
LEXX vs. S&P 500
-
Over the past 5 trading days, Lexaria Bioscience Corp. has underperformed the S&P 500 by -27.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lexaria Bioscience Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexaria Bioscience Corp. has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Lexaria Bioscience Corp. reported revenues of $174K.
Earnings Growth
-
Lexaria Bioscience Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Lexaria Bioscience Corp. reported earnings per share of -$0.14.
Enterprise value:
13.2M
EV / Invested capital:
--
Price / LTM sales:
15.82x
EV / EBIT:
--
EV / Revenue:
18.68x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$615.4K
Return On Assets:
-129.26%
Net Income Margin (TTM):
-1851.08%
Return On Equity:
-147.19%
Return On Invested Capital:
-144.76%
Operating Margin:
-2155.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Income Statement | ||||||
| Revenue | $226.2K | $464.3K | $705.9K | $84K | $174K | |
| Gross Profit | $194.7K | $372.4K | $615.4K | $67.6K | $152.6K | |
| Operating Income | -$6.5M | -$5.7M | -$11.6M | -$2.2M | -$2.5M | |
| EBITDA | -$6.4M | -$5.6M | -$11.5M | -$2.2M | -$2.5M | |
| Diluted EPS | -$1.01 | -$0.46 | -$0.66 | -$0.14 | -$0.14 | |
| Period Ending | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.4M | $7M | -- | $7.9M | $3.5M | |
| Total Assets | $13.3M | $7.8M | -- | $8.9M | $4.2M | |
| Current Liabilities | $153.3K | $194K | -- | $1.1M | $1.5M | |
| Total Liabilities | $203.3K | $201.4K | -- | $1.2M | $1.6M | |
| Total Equity | $13.1M | $7.6M | -- | $7.7M | $2.6M | |
| Total Debt | $97.3K | $7.4K | -- | $109.3K | $78.9K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$5M | -$10.5M | -$1.9M | -$2.6M | |
| Cash From Investing | -- | -$188.6K | -$243K | -$69.6K | -$157.9K | |
| Cash From Financing | -- | $10.3M | $6M | -- | -- | |
| Free Cash Flow | -$6.1M | -$5.1M | -$10.6M | -$2M | -$2.7M | |
LEXX
Sector
Market Cap
$15.4M
$28.1M
Price % of 52-Week High
25.51%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-30.27%
-1.49%
1-Year Price Total Return
-71.82%
-17.13%
Beta (5-Year)
0.628
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.87
200-day SMA
Sell
Level
$1.08
Bollinger Bands (100)
Sell
Level
0.82 - 1.16
Chaikin Money Flow
Sell
Level
-829.2K
20-day SMA
Sell
Level
$1.00
Relative Strength Index (RSI14)
Sell
Level
34.97
ADX Line
Sell
Level
29.53
Williams %R
Buy
Level
-85.4167
50-day SMA
Sell
Level
$1.00
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Sell
Level
-2.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-23.168)
Sell
CA Score
(Annual)
Level (-6.8793)
Buy
Beneish M-Score
(Annual)
Level (-5.034)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (19.2887)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Stock Forecast FAQ
In the current month, LEXX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LEXX average analyst price target in the past 3 months is $6.00.
-
Where Will Lexaria Bioscience Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexaria Bioscience Corp. share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Lexaria Bioscience Corp.?
Analysts are divided on their view about Lexaria Bioscience Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexaria Bioscience Corp. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Lexaria Bioscience Corp.'s Price Target?
The price target for Lexaria Bioscience Corp. over the next 1-year time period is forecast to be $6.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LEXX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexaria Bioscience Corp. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of LEXX?
You can purchase shares of Lexaria Bioscience Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexaria Bioscience Corp. shares.
-
What Is The Lexaria Bioscience Corp. Share Price Today?
Lexaria Bioscience Corp. was last trading at $0.57 per share. This represents the most recent stock quote for Lexaria Bioscience Corp.. Yesterday, Lexaria Bioscience Corp. closed at $0.67 per share.
-
How To Buy Lexaria Bioscience Corp. Stock Online?
In order to purchase Lexaria Bioscience Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LEXX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LEXX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.02x
-0.01x
P/B ratio
5.16x
1.81x
Price / LTM sales
15.82x
1.59x
Growth Metrics
LEXX
Sector
Revenue growth
107.14%
4.62%
Earnings growth
0.29%
11.06%
Revenue (5-year growth)
17.53%
6.5%
Earnings forecast
--
-$0.21
Profitability
LEXX
Sector
Profitability FY 2025
$587.4K
$3.6M
Return on invested capital
-144.76%
-31.84%
Return on assets
-129.26%
-27.96%
Return on equity
-147.19%
-37.63%
Earnings Date
Last Earnings Date
Dec
24
Next Earnings Date
Dec
24
Estimated Next Earnings Date
Mar
25
Balance Sheet
LEXX
Sector
Total cash
$2M
$26.4M
Short term investments
$55.8K
$25.7M
Total assets
$4.2M
$76.9M
Long term debt
$116.6K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
